European Commission Approves Obinutuzumab for Previously Untreated Advanced Follicular Lymphoma

October 5, 2017 – On September 22, Roche announced that the European Commission has approved obinutuzumab in combination with chemotherapy, followed by obinutuzumab maintenance in patients achieving a response, as a new treatment for previously untreated advanced follicular lymphoma. The approval is based on results from the GALLIUM study, the first phase III study in previously untreated follicular lymphoma to show superior progression-free … (leggi tutto)